{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:32:37Z","timestamp":1761611557035,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00280-023-04505-y","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T17:03:07Z","timestamp":1677690187000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Determination of 5-azacitidine in human plasma by LC\u2013MS\/MS: application to pharmacokinetics pilot study in MDS\/AML patients"],"prefix":"10.1007","volume":"91","author":[{"given":"Melanie","family":"Donnette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Osanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Giocanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffroy","family":"Venton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Farnault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Berda-Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solas","family":"Caroline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.\u2019Houcine","family":"Ouafik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6750-4658","authenticated-orcid":false,"given":"Rapha\u00eblle","family":"Fanciullino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"4505_CR1","unstructured":"50\u2013794_Vidaza_Pharmr_P1.pdf, (n.d.). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/50-794_Vidaza_Pharmr_P1.pdf (accessed August 27, 2021)."},{"key":"4505_CR2","doi-asserted-by":"publisher","first-page":"28812","DOI":"10.18632\/oncotarget.15807","volume":"8","author":"M Tobiasson","year":"2017","unstructured":"Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, Paepe AD, Karimi M, Krjutskov K, Einarsdottir E, Gr\u00f6vdal M, Jansson M, Azenkoud AB, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellstr\u00f6m-Lindberg E, Ungerstedt J (2017) Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive\/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease. Oncotarget 8:28812\u201328825. https:\/\/doi.org\/10.18632\/oncotarget.15807","journal-title":"Oncotarget"},{"key":"4505_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8\u201313. https:\/\/doi.org\/10.1002\/ijc.23607","journal-title":"Int J Cancer"},{"key":"4505_CR4","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","volume":"383","author":"L Ad\u00e8s","year":"2014","unstructured":"Ad\u00e8s L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. Lancet Lond Engl 383:2239\u20132252. https:\/\/doi.org\/10.1016\/S0140-6736(13)61901-7","journal-title":"Lancet Lond Engl"},{"key":"4505_CR5","doi-asserted-by":"publisher","first-page":"e0169128","DOI":"10.1371\/journal.pone.0169128","volume":"12","author":"C Min","year":"2017","unstructured":"Min C, Moore N, Shearstone JR, Quayle SN, Huang P, van Duzer JH, Jarpe MB, Jones SS, Yang M (2017) Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia. PLoS ONE 12:e0169128. https:\/\/doi.org\/10.1371\/journal.pone.0169128","journal-title":"PLoS ONE"},{"key":"4505_CR6","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042\u20132054. https:\/\/doi.org\/10.1056\/NEJMra023075","journal-title":"N Engl J Med"},{"key":"4505_CR7","unstructured":"vidaza-epar-product-information_fr.pdf, (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vidaza-epar-product-information_fr.pdf (accessed September 6, 2021)."},{"key":"4505_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","volume":"133","author":"V Santini","year":"2019","unstructured":"Santini V (2019) How I treat MDS after hypomethylating agent failure. Blood 133:521\u2013529. https:\/\/doi.org\/10.1182\/blood-2018-03-785915","journal-title":"Blood"},{"issue":"Suppl 3","key":"4505_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-011-0002-8","volume":"28","author":"P Font","year":"2011","unstructured":"Font P (2011) Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia. Adv Ther 28(Suppl 3):1\u20139. https:\/\/doi.org\/10.1007\/s12325-011-0002-8","journal-title":"Adv Ther"},{"key":"4505_CR10","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/cncr.33472","volume":"127","author":"M Clavio","year":"2021","unstructured":"Clavio M, Cris\u00e0 E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Santini V (2021) Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer 127:2015\u20132024. https:\/\/doi.org\/10.1002\/cncr.33472","journal-title":"Cancer"},{"key":"4505_CR11","unstructured":"onureg-epar-public-assessment-report_en.pdf, (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/onureg-epar-public-assessment-report_en.pdf (accessed May 3, 2022)."},{"key":"4505_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/FPC.0000000000000139","volume":"25","author":"R Fanciullino","year":"2015","unstructured":"Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R (2015) Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome, Pharmacogenet. Genomics 25:317\u2013321. https:\/\/doi.org\/10.1097\/FPC.0000000000000139","journal-title":"Genomics"},{"key":"4505_CR13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2217\/pgs.15.135","volume":"16","author":"R Fanciullino","year":"2015","unstructured":"Fanciullino R, Mercier C, Serdjebi C, Venton G, Colle J, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R (2015) Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. Pharmacogenomics 16:1907\u20131912. https:\/\/doi.org\/10.2217\/pgs.15.135","journal-title":"Pharmacogenomics"},{"key":"4505_CR14","unstructured":"Fiche info - VIDAZA 25 mg\/ml poudre pour suspension injectable - Base de donn\u00e9es publique des m\u00e9dicaments, (n.d.). https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=61118337 (accessed September 13, 2021)."},{"key":"4505_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.pharma.2013.06.002","volume":"71","author":"J Vigneron","year":"2013","unstructured":"Vigneron J, Astier A, Trittler R, Hecq JD, Daouphars M, Larsson I, Pourroy B, Pinguet F (2013) SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr 71:376\u2013389. https:\/\/doi.org\/10.1016\/j.pharma.2013.06.002","journal-title":"Ann Pharm Fr"},{"key":"4505_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/molecules19010342","volume":"19","author":"D Li","year":"2013","unstructured":"Li D, Zhang T, Kou L, Zhang Y, Sun J, He Z (2013) Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of azacitidine in rat plasma and its application to a bioavailability study. Mol Basel Switz 19:342\u2013351. https:\/\/doi.org\/10.3390\/molecules19010342","journal-title":"Mol Basel Switz"},{"key":"4505_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jchromb.2004.09.012","volume":"813","author":"M Zhao","year":"2004","unstructured":"Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD (2004) Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 813:81\u201388. https:\/\/doi.org\/10.1016\/j.jchromb.2004.09.012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4505_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/bmc.3562","volume":"30","author":"NM Anders","year":"2016","unstructured":"Anders NM, Wanjiku TM, He P, Azad NS, Rudek MA (2016) A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. Biomed Chromatogr 30:494\u2013496","journal-title":"Biomed Chromatogr"},{"key":"4505_CR19","unstructured":"guideline-bioanalytical-method-validation_en.pdf, (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf (accessed June 13, 2022)."},{"key":"4505_CR20","unstructured":"C. for D.E. and Research, Bioanalytical Method Validation Guidance for Industry, US Food Drug Adm. (2020). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry (accessed September 14, 2021)."},{"key":"4505_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2009.24.4491","volume":"28","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini J, Dahan L, Andr\u00e9 N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz J-F, Mercier C (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol Off J Am Soc Clin Oncol 28:160\u2013165. https:\/\/doi.org\/10.1200\/JCO.2009.24.4491","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4505_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1182\/bloodadvances.2017014126","volume":"2","author":"R Fanciullino","year":"2018","unstructured":"Fanciullino R, Farnault L, Donnette M, Imbs D-C, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R (2018) CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Adv 2:462\u2013469. https:\/\/doi.org\/10.1182\/bloodadvances.2017014126","journal-title":"Blood Adv"},{"key":"4505_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.annonc.2021.01.072","volume":"32","author":"M Donnette","year":"2021","unstructured":"Donnette M, Ciccolini J, Pissier C, Costello R, Duffaud F, Salas S, Farnault L, Tichadou A, Arcani R, Jarrot PA, Ouafik LH, Venton G, Fanciullino R (2021) High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications. Ann Oncol Off J Eur Soc Med Oncol 32:684\u2013686. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.072","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4505_CR24","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","volume":"19","author":"RZ Mahfouz","year":"2013","unstructured":"Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y (2013) Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy, Clin Cancer Res Off J Am Assoc. Cancer Res 19:938\u2013948. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1722","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04505-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04505-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04505-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T11:04:48Z","timestamp":1679483088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04505-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4505"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04505-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}